OSCR
Oscar Health, Inc.
OSCR's fundamentals are strong: revenue grew 55% and its operating margin went from −1.9% to 5.4%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
XFOR
X4 Pharmaceuticals, Inc.
There isn't enough reported data to score XFOR yet.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
XFOR Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Under pressure | |
| Unavailable |
XFOR's revenue is currently healthy, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
XFOR PE Valuation
XFOR has no meaningful PE right now: it lost money over the past year.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
XFOR Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Growth | |
| -- | |
| Limited | |
| Moderate |
Analysts expect XFOR's revenue to grow, with its earnings and profitability holding steady.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the stronger earnings trend. Trailing diluted EPS is up 147% for OSCR versus XFOR down 662%.
XFOR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2025 | -$10.12 | -$8.32 |
| Q2 2025 | -$14.83 | -549% |
| Q1 2025 | $2.14 | +$22.24 |
| Q4 2024 | -$5.70 | +$11.40 |
| Q3 2022 | -$83.10 | +$27.90 |
| Q2 2022 | -$98.10 | +$16.20 |
| Q1 2022 | -$102.30 | +$12.60 |
| Q4 2021 | -$119.70 | -$27.00 |
XFOR is still losing money, but far less than before: $10.12 per share over the past year, against $119.70 at its worst in late 2021.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over XFOR on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over XFOR on profitability, with a higher operating margin.
XFOR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $2.8M | +79% |
| Q2 2026 | $2.4M | +38% |
| Q1 2026 | $2.5M | +178% |
| Q4 2025 | $2.2M | +53% |
| Q3 2025 | $1.6M | +180% |
| Q2 2025 | $1.7M | +210% |
XFOR's revenue has grown year over year for 10 quarters in a row: $3M last quarter, up 79% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -714% | +1043 points |
| Q2 2026 | -683% | +821 points |
| Q1 2026 | -812% | +237 points |
| Q4 2025 | -1077% | +1413 points |
| Q3 2025 | -1757% | +4404 points |
| Q2 2025 | -1504% | -14133 points |
| Q1 2025 | -1049% | N/A |
| Q4 2024 | -2491% | N/A |
XFOR's operating margin was −714% last quarter, up 1043 points from the same quarter a year ago.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over XFOR on cash generation, producing positive trailing cash flow while its opponent burns cash.
XFOR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$20.2M | +$7.6M |
| Q2 2026 | -$20.8M | +$9.1M |
| Q1 2026 | -$19.6M | -$7.2M |
| Q4 2025 | -$15.5M | +$17.5M |
| Q3 2025 | -$27.8M | +$6.3M |
| Q2 2025 | -$29.9M | +$34.1M |
| Q1 2025 | -$12.4M | +$21.3M |
| Q4 2024 | -$33M | -$5.3M |
XFOR has burned cash in almost every quarter: −$76M over the past year, against −$103M the year before.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has the edge over XFOR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
XFOR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.1% | +180K shares |
| 1 year | +1607% | +119M shares |
| 3 years | +2149% | +121M shares |
| 5 years | +18192% | +126M shares |
| Available history | +18865% | +126M shares |
XFOR has 127M diluted shares, up 1607% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2023 | $443,000 |
| Q4 2022 | — |
| Q4 2021 | — |
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
XFOR Net Leverage
XFOR's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
XFOR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.7 | Neutral |
| Stochastic | 34.5 | Neutral |
XFOR's weekly RSI is 44 (neutral) and its Stochastic is 35 (neutral).
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
XFOR PE vs Healthcare Sector
| Metric | XFOR | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
XFOR has no meaningful PE right now: it lost money over the past year.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over XFOR on trend strength, trading above more of its moving averages.
XFOR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.04 | 4.3% above |
| 20 week MA | $3.63 | 13% below |
| 50 week MA | $3.81 | 17% below |
| 100 week MA | $5.35 | 41% below |
| 200 week MA | $18.2 | 83% below |
XFOR has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 83% below its 200-week average.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over XFOR on returns for 2026, with the stronger performance.
XFOR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $325.8 | $210.3 | -35% |
| 2021 | $210.3 | $74.1 | -65% |
| 2022 | $74.1 | $25.8 | -65% |
| 2023 | $25.8 | $25.2 | -2.6% |
| 2024 | $25.2 | $24.1 | -4.1% |
| 2025 | $24.1 | $4.50 | -81% |
| 2026 YTD | $4.50 | $3.17 | -30% |
XFOR has finished every year since 2020 lower, and it's down 30% so far in 2026.